International Edition

Thursday, 3 September 2026

Private Trade News

Global markets, trading & world business — for professional traders

Markets

Revolution Medicines (BMV:RVMD) Consensus Price Target Increased by 30.66% to MX$3,921.29

· Nasdaq

The average one-year price target for Revolution Medicines (BMV:RVMD) has been revised to MX$3,921.29 / share. This is an increase of 30.66% from the prior estimate of MX$3,001.13 dated August 3, 2026.

The price target is an average of many targets provided by analysts. The latest targets range from a low of MX$2,837.87 to a high of MX$5,274.21 / share.

There are 273 funds or institutions reporting positions in Revolution Medicines. This is an increase of 21 owner(s) or 8.33% in the last quarter. Average portfolio weight of all funds dedicated to RVMD is 0.54%, an increase of%. Total shares owned by institutions increased in the last three months by 22.68% to 61,778K shares.

Farallon Capital Management holds 13,551K shares representing 20.35% ownership of the company. In its prior filing, the firm reported owning 13,605K shares , representing a decrease of 0.40%. The firm increased its portfolio allocation in RVMD by 55.24% over the last quarter.

Baker Bros. Advisors holds 11,443K shares representing 17.18% ownership of the company. In its prior filing, the firm reported owning 9,555K shares , representing an increase of 16.50%. The firm increased its portfolio allocation in RVMD by 101.28% over the last quarter.

Jupiter Topco holds 10,736K shares representing 16.12% ownership of the company.

Darwin Global Management holds 10,630K shares representing 15.96% ownership of the company. In its prior filing, the firm reported owning 2,211K shares , representing an increase of 79.20%. The firm increased its portfolio allocation in RVMD by 901.64% over the last quarter.

Janus Henderson Group holds 9,766K shares representing 14.66% ownership of the company. In its prior filing, the firm reported owning 12,304K shares , representing a decrease of 25.98%. The firm increased its portfolio allocation in RVMD by 7.28% over the last quarter.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.